News

John R. van Nagell, Jr. has worked with countless patients, faculty and students, but his lasting legacy will likely be the Ovarian Cancer Screening Program at the Markey Cancer Center.

Dr. John van Nagell spent his career at UK diagnosing and treating patients, and mentoring and teaching young doctors, but his lasting legacy will likely be his research.

A newly proposed clinical trial could change how deadly triple-negative breast cancer is treated.

Stamm's work shows the function of snoRNAs in regulating alternative splicing.

Doug Andres is exploring the link between RIT1 mutations and lung cancer.

Fifteen years ago Douglas Andres and his team produced data that showed mutations in an on-off switch called RIT1 are a novel driver for human lung cancer.

Donna Arnett talks about her first research project, why she can't quit research, and her vision for the College of Public Health.

Jenna Hatcher is taking preventive health care into the emergency department, “because for many Kentuckians that’s where they find their medical home."

John D'Orazio studies hormonal pathways that protect the skin from sun damage and repair DNA.

A new metabolomics study suggests targeting a key enzyme may lead to novel drug development for lung cancer.